AKBA Quote, Financials, Valuation and Earnings

Ardelyx has a net margin of 10.66% compared to Akebia Therapeutics's net margin of -55.52%. Akebia Therapeutics's return on equity of -- beat Ardelyx's return on equity of -34.68%.

Akebia Therapeutics has a consensus price target of $7.40, signalling upside risk potential of 90.72%. On the other hand Ardelyx has an analysts' consensus of $10.91 which suggests that it could grow by 141.35%. Given that Ardelyx has higher upside potential than Akebia Therapeutics, analysts believe Ardelyx is more attractive than Akebia Therapeutics.

Akebia Therapeutics has a beta of 0.882, which suggesting that the stock is 11.791% less volatile than S&P 500. In comparison Ardelyx has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.538%.

Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. Ardelyx pays out -- of its earnings as a dividend.

Akebia Therapeutics quarterly revenues are $57.3M, which are smaller than Ardelyx quarterly revenues of $74.1M. Akebia Therapeutics's net income of $6.1M is higher than Ardelyx's net income of -$41.1M. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while Ardelyx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 4.62x versus 2.96x for Ardelyx. Usually stocks with elevated PS ratios are considered overvalued.

Blueprint Medicines has a net margin of 10.66% compared to Akebia Therapeutics's net margin of 0.33%. Akebia Therapeutics's return on equity of -- beat Blueprint Medicines's return on equity of -49.13%.

Akebia Therapeutics has a consensus price target of $7.40, signalling upside risk potential of 90.72%. On the other hand Blueprint Medicines has an analysts' consensus of $126.87 which suggests that it could fall by -2%. Given that Akebia Therapeutics has higher upside potential than Blueprint Medicines, analysts believe Akebia Therapeutics is more attractive than Blueprint Medicines.

Akebia Therapeutics has a beta of 0.882, which suggesting that the stock is 11.791% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.894, suggesting its less volatile than the S&P 500 by 10.564%.

Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.

Akebia Therapeutics quarterly revenues are $57.3M, which are smaller than Blueprint Medicines quarterly revenues of $149.4M. Akebia Therapeutics's net income of $6.1M is higher than Blueprint Medicines's net income of $496K. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 4.62x versus 14.76x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

Heron Therapeutics has a net margin of 10.66% compared to Akebia Therapeutics's net margin of 6.77%. Akebia Therapeutics's return on equity of -- beat Heron Therapeutics's return on equity of --.

Akebia Therapeutics has a consensus price target of $7.40, signalling upside risk potential of 90.72%. On the other hand Heron Therapeutics has an analysts' consensus of $6.25 which suggests that it could grow by 212.5%. Given that Heron Therapeutics has higher upside potential than Akebia Therapeutics, analysts believe Heron Therapeutics is more attractive than Akebia Therapeutics.

Akebia Therapeutics has a beta of 0.882, which suggesting that the stock is 11.791% less volatile than S&P 500. In comparison Heron Therapeutics has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.163%.

Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Heron Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. Heron Therapeutics pays out -- of its earnings as a dividend.

Akebia Therapeutics quarterly revenues are $57.3M, which are larger than Heron Therapeutics quarterly revenues of $38.9M. Akebia Therapeutics's net income of $6.1M is higher than Heron Therapeutics's net income of $2.6M. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while Heron Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 4.62x versus 2.06x for Heron Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of 10.66% compared to Akebia Therapeutics's net margin of 4.19%. Akebia Therapeutics's return on equity of -- beat TG Therapeutics's return on equity of 19.78%.

Akebia Therapeutics has a consensus price target of $7.40, signalling upside risk potential of 90.72%. On the other hand TG Therapeutics has an analysts' consensus of $40.50 which suggests that it could grow by 3.34%. Given that Akebia Therapeutics has higher upside potential than TG Therapeutics, analysts believe Akebia Therapeutics is more attractive than TG Therapeutics.

Akebia Therapeutics has a beta of 0.882, which suggesting that the stock is 11.791% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 1.913, suggesting its more volatile than the S&P 500 by 91.257%.

Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Akebia Therapeutics quarterly revenues are $57.3M, which are smaller than TG Therapeutics quarterly revenues of $120.9M. Akebia Therapeutics's net income of $6.1M is higher than TG Therapeutics's net income of $5.1M. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 163.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 4.62x versus 16.31x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.